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Current research is showing an increas-
ing heterogeneity in the binding sites
available in NTTs. These binding sites
are often located distant from the central
binding sites, suggesting a higher level of
complexity in the regulation of NTT
function.
Allosteric sites increase specificity, re-
ducing off-target effects.
Small molecules can be developed to
target NTT allosteric sites, with the possi-
bility to either increase or decrease their
functions.
NTT allosteric modulators are in ad-
vanced clinical trials, emphasizing their
potential for the treatment of neuropsy-
chiatric disorders.
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(H.H. Sitte).Neurotransmitter transporters (NTTs) are involved in the fine-tuning of brain neu-
rotransmitter homeostasis. As such, they are implicated in a plethora of complex
behaviors, including reward, movement, and cognition. During recent decades,
compounds that modulate NTT functions have been developed. Some of them
are in clinical use for the management of different neuropsychiatric conditions.
The majority of these compounds have been found to selectively interact with
the orthosteric site of NTTs. Recently, diverse allosteric sites have been de-
scribed in a number of NTTs, modulating their function. A more complex NTT
pharmacology may be useful in the development of novel therapeutics. Here,
we summarize current knowledge on such modulatory allosteric sites, with spe-
cific focus on their pharmacological and therapeutic potential.
Neurotransmitter Transporters – Key Regulators of Synaptic Transmission
Synaptic transmission is a fundamental feature of the communication between neurons [1]. After
the quantal presynaptic release of neurotransmitter into the synaptic cleft, binding to pre- and
postsynaptic receptors follows. Subsequently, the signal is quickly terminated by efficient reup-
take of the neurotransmitter back into the presynaptic neuron (Figure 1A). Reuptake is tightly reg-
ulated by neurotransmitter transporters (NTTs), a class of complex molecules, each holding
specificity for only one or a few neurotransmitters. For instance, the dopamine and norepineph-
rine transporter (DAT and NET, respectively) can efficiently uptake both dopamine and norepi-
nephrine with similar kinetics [2,3], while the serotonin transporter (SERT) can efficiently
transport serotonin but only binds dopamine with very low affinity [4]. Once inside the presynaptic
neuron, the neurotransmitters are, in general, rapidly confined into vesicles by specific vesicular
transporters (Figure 1A, grey transporter), in order to prevent toxicity [5]. The rapid removal of
neurotransmitters from extracellular fluids avoids an exaggerated signal and confines the neuro-
transmitters within the intended area, preventing chemical crosstalk [6] (Figure 1). Because of
their important role in synaptic transmission, dysfunctional or improper regulation of the NTTs
contribute to neurological and neuropsychiatric disorders [7]. Therefore, NTTs are also clinically
relevant pharmacological targets for the treatment of major neuropsychiatric diseases, such as
depression, attention-deficit hyperactivity disorder, epilepsy, and narcolepsy [8].
General Structure and Mechanism of Function of NTTs
All NTTs require the concentrating power of specific ions in order for the substrate to accumulate
on its respective side of the membranes. The type and the stoichiometry of different ions vary
among NTTs. In general, Na+ and Cl– are required in the case of DAT, NET, and SERT, and
Na+ and K+ in the case of the excitatory amino acid transporters (EAATs) 1–5. Ionic concentration
underlies the ability of the NTTs to accumulate substrate on one side of the cellular membrane
[8,9].
NTT structure can vary quite a lot between different classes of transporter, for instance, DAT,
NET, and SERT are organized in 12 transmembrane helixes (TM), while other NTTs such as446 Trends in Pharmacological Sciences, July 2020, Vol. 41, No. 7 https://doi.org/10.1016/j.tips.2020.04.006
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Glossary
Cooperativity: the effect a ligand has
on the binding of a second ligand.
Full release: pharmacological agents
like D-amphetamine,
methamphetamine, para-chloro-
amphetamine, or MDMA can elicit a
pronounced efflux of neurotransmitters,
also known as full release.
Partial release: some pharmacological
agents can mediate a reduced maximal
efflux of neurotransmitter (partial release)
when compared with a full-releaser.
Partial releasers are included in the
nonclassical pharmacology of NTTs.
Use-dependency: the ability of a drug
to bind its target only when in a specific
state, (e.g., only when it is in its active
form or ‘in use’).
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Figure 1. Neurotransmitter Transporters (NTTs) Regulate the Neurotransmitter Signal. (A) Neurotransmitters are
rapidly removed from the synapse by NTTs present in the presynaptic neurons (red transporter), after being released into the
extracellular space. By exerting their functions, NTTs regulate the concentration of neurotransmitters available for pre- and
postsynaptic receptors. Depending on the activity of the NTT, the diffusion area of the neurotransmitter can change and
influence cellular processes far from the releasing site. Once reuptake into the presynaptic neuron has occurred, the
neurotransmitter is rapidly removed from the cytoplasm and packed into vesicles by vesicular transporters (grey
transporter). (B) NTTs have a common general structure composed of a vestibule, leading to the orthosteric site. The
orthosteric site is located between an extracellular and intracellular gate (top panel). Before binding the substrate and the
cosubstrate, the NTT is in its outward-facing conformation (‘To’, bottom panel). In this conformation the transporter binds
first Na+ (‘ToNa’) and then the substrate (‘ToNaS’). Together, these binding events allow the NTT to flip from the outward-
facing conformation to the inward-facing conformation (‘TiNaS’). Na+ and S can now be released in the cytoplasm (‘TiS’
and ‘Ti’) and the NTT can return to the outward-facing conformation.
Trends in Pharmacological SciencesEAATs are instead organized in eight TMs. These TMs are connected by extracellular and intra-
cellular loops, which work as regulatory sites through different post-translational modifications
such as phosphorylation and glycosylation [10,11]. As far as NTTs are concerned, the 3D orga-
nization of the different TMs and loops determine a complex structure composed of a vestibule
leading to the central binding site confined between an extracellular gate and an intracellular
gate (Figure 1B) [8,12]. The dynamics of this structure follow the so-called ‘alternate access
model’: upon binding of substrate and ions, an extracellular gate seals off the binding site and
the protein alternates conformation between outward- and inward-facing modes, resulting in
the transport of the substrate across themembrane [13] (Figure 1B, bottom). This alternating pro-
cess has been suggested to pass through different intermediate configurations, which are regu-
lated in concert by the substrate and ions and is known as ‘the transport cycle’ [14,15].
Transport Cycle and Transporter-Mediated Currents
NTTs are secondary active transporters and therefore they couple substrate transport to the elec-
trochemical gradient of Na+. Most of them cotransport Cl– and some of them counter-transport
K+ or H+ [8].Trends in Pharmacological Sciences, July 2020, Vol. 41, No. 7 447
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outward-facing conformation (To) needs to first bind Na+ (ToNa) and then the substrate
(ToNaS) before it can transition to the inward-facing conformation (TiNaS). At this point, since
the internal concentration of Na+ and S is very low, they can dissociate from the transporter
(TiS and Ti) and the transporter in the inward-facing conformation can now return to the
outward-facing conformation (To). In some cases, other ions (e.g., K+ and/or H+ in the case of
SERT [16]) can modulate the dissociation of the substrate (S) internally and therefore regulate
the efficiency of the transport process.
The coupling between substrate and ions during the transport process results in the so-called
‘transporter-mediated currents’ that can be monitored by means of a whole-cell patch clamp
(for a detailed review, consider [17]).
The typical transporter-mediated current is an inwardly-directed current. These are voltage-
dependent and can be elicited by applying the substrate with a perfusion device able to switch
between different solutions within 50–100ms [16,18,19]. When cells are clamped at negative po-
tential and under physiological conditions, they show a so-called ‘steady-state current’, which is
present until the substrate is continuously applied to the cell, then decays back to the baseline as
soon as the substrate is no longer present (see Figure IC in Box 1). This has been shown to be
representative of the transporter completing the transport cycle and is therefore an average of
all the charge movements happening during the transport cycle (see Figure IC in Box 1, bottom,Box 1. Methods for Studying Allosteric Modulation of Transporters
Hill-Langmuir Equation
The Hill-Langmuir equation describes the occupancy of a receptor by its ligand.
θ ¼ L½ 
η
Kd þ L½ η
¼ 1
1þ KA
L½ 
 η
where θ is the fraction of the receptor–ligand complex, [L] is the concentration of unbound ligand, Kd is the dissociation constant, Ka is the ligand concentration produc-
ing half occupation, and η is the Hill coefficient assuming any positive value [53,131]; η describes the degree of cooperativity between multiple binding sites for the same
ligand. With η = 1 there is no cooperativity, with η N 1 the cooperativity is positive, and with η b 1 it is negative [53] (Figure IA).
Uptake (Saturation) Experiments
Classical uptake-saturation experiments are conducted in the presence of different concentrations of a putative allosteric ligand. The Michaelis-Menten parameters
(Km and Vmax) are derived from the dose response curves using a linearized form of the Lineweaver-Burk plot or the Eadie-Hofstee diagram. Direct nonlinear re-
gression analysis of the dose response data allows for alleviating the limitations of the linearized equations. Extrapolation of the Lineweaver-Burk plot to the ab-
scissa for two measurements in the presence or absence of a second ligand allows for a simple detection of competitive or noncompetitive interaction (Figure IB).
Alternatively, coupling between substrate and ions during the transport process generates transporter-mediated currents (measured electrophysiologically), which can be
used as a surrogate of NTT activity (Figure IC). The whole-cell patch clamp approach provides access to the internal side of the cell. By changing the ionic compositions
inside and outside of the cell, it is possible to isolate different components of the current (i.e., the steady-state, representing an average of all the transport partial reactions,
and the peak, representing the outward-open, ToSNa, to inward-open transition, TiSNa) and to study partial reactions of the transport cycle [14,23] (Figure IC).
Dissociation Experiments
Allosteric ligands can change the dissociation of a prebound inhibitor. In brief, membrane preparations containing the protein of interest are incubated with a high affinity
[3H]inhibitor. After the equilibrium is reached, the ligand of interest is added to the preparation and the reaction is stopped at different time-points. If the ligand binds to an
allosteric site that increases the affinity in the central binding site, the dissociation rate is reduced [66] (Figure ID).
Atomic Force Microscopy (AFM)
AFM can be used to study interactions of ligands and proteins at a single molecule level in native tissues. In brief, the tip of a highly sensitive cantilever is functionalized
with the putative allosteric ligand and incubated with the cells expressing the desired transporter. Once at equilibrium, the AFM tip is lifted up and the bending of the
cantilever allows the quantification of distribution of forces. A binomial distribution is indicative of a secondary binding site [69,132] (Figure IE).
448 Trends in Pharmacological Sciences, July 2020, Vol. 41, No. 7
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Figure I. Methods to Study Allosteric Modulation of Transporters. (A) Representative graph shows depiction of Hill-Langmuir equation with change in the slope of
the sigmoidal curve as a function of the cooperativity η. (B) Saturation of uptake experiments can be combined with nonlinear regression to calculate Km and Vmax, allowing
for the identification of the specific type of allosteric modulation. Common types are competitive inhibition (left) and noncompetitive (right) allosteric modulation. In the insets,
the respective Lineweaver-Burk plots are displayed. The use of nonlinear regression to identify the type of allosteric modulation has partially substituted the use of different
types of Michaelis-Menten linearization for the calculation of Km and Vmax. However, linearization is still widely used, because it allows a visual assessment of changes in Km
and Vmax (B, bottom panels). In addition to the Lineweaver-Burk plot [133], the Hofstee [134] or the Eadie-Hofstee method [135] are also commonly used. (C)
Representative trace of transporter-mediated current measured by electrophysiology and a simplified version of the transport cycle is shown. Note that different
components of the current correspond to different partial reactions (blue versus red in the scheme). (D) Representative graph showing the reduction in the dissociation
half-life of a radioactive tracer (S1, blue) mediated by the binding of an allosteric modulator (S2, cyan). (E) Schematic representation of the interaction between the
binding sites of the transporter and the motion-sensitive cantilever (highlighted) with the attached ligand [bottom: S1-site (= orthosteric site), top: S2-site (= allosteric
site)]. The probability of unbinding the ligand from these sites can be plotted against the force applied to obtain a unimodal or multimodal distribution. This depends on
whether one or more sites are involved in the binding of the ligand. Abbreviations: NTT, neurotransmitter transporters; PDF, probability density function.
Trends in Pharmacological Sciencesblue and red). In some transporters, a peak current can also be present (see Figure IC in Box 1, top,
red). If present, the peak current contains information about the outward-open to the inward-open
transition and it can be elicited either by substrate application or by binding of inhibitors [20–23].Trends in Pharmacological Sciences, July 2020, Vol. 41, No. 7 449
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substituting different ions or introducing compounds into the patch pipette, it is possible to isolate dif-
ferent states of the transport cycle and extract rate constants of all these partial reactions. These con-
stants can then be used for developing kinetic models of the transport cycle [15]. Detailed kinetic
models exist already for GABA transporter-1 (GAT-1) [24], DAT [25], SERT [16,26,27], and glycine
transporters GlyT1 [28] and GlyT2 [28]. Keeping in mind the information present in such kinetic
models during drug development may help in understanding differences between apparently similar
drugs and transporters and provide information about allosteric effects [14,19,29,30].
NTTs: The Input/Output Neurotransmission System
Not only do transporters participate in the reuptake of neurotransmitters, shaping the input sig-
naling (i.e., receptor activity), but they can also reverse their transport direction and release neu-
rotransmitters in an exocytosis-independent manner and therefore participate in output signals.
This process, also known as transporter-mediated ‘efflux’, has been mainly described for phar-
macological agents like amphetamine and congeners targeting monoamine transporters [31].
As substrates of these transporters, they interact with the proton-driven vesicular monoamine
transporters (VMATs) and are translocated into vesicles, dissipating their proton gradient and
redistributing the vesicle content [32] (Figure 1A). Concomitantly, amphetamines inhibit the
activity of monoamine oxidases (MAO) [33], catechol-O-methyl-transferase (COMT), and activate
different kinases (e.g., alpha-CamKII or protein kinase C [34]). The combined actions on the
VMAT, MAO, and COMT determine the cytosolic increase in the endogenous neurotransmitter
(e.g., dopamine). When the concentration of neurotransmitter is high enough in the presence of
Na+, it can bind to the intracellular side of the NTT and translocate to the extracellular space [31].
In the case of SERT, this pharmacologically induced efflux has been recently suggested as a re-
quired mechanism for the prosocial effect of 3,4-methylenedioxy-N-methylamphetamine
(MDMA), also known as ‘ecstasy’ [35], which is currently under clinical evaluation for the treat-
ment of social anxiety symptoms in post-traumatic disorder [36] and autism [37].
However, efflux can also happen in a pharmacologically independent way. During ischemia, ATP
levels decrease and affect the function of the Na+/K+-ATPase. This leads to an increase of extra-
cellular K+, which in turn reverses glutamate transport and thereby triggers neuronal death due to
excitotoxicity [38]. In the case of early-onset Parkinsonism, a coding variant has been identified,
the DAT-Asp421Asn, characterized by a constitutive, anomalous dopamine efflux [39]. A similar
alteration in the coding variant DAT-T356M has also been identified in autism [40,41].
Taken together, these studies suggest that NTT-mediated efflux could be potentially targeted for
the development of future medications. However, future research will be required to expand on
this important function of NTTs.
The Complex Pharmacology of NTTs
The complexity of the NTT–ligand interaction can be gauged by several examples: amphetamine,
for instance, is a substrate of monoamine transporters [31]; however, amphetamine is often de-
scribed as an inhibitor because of its inhibitory action on dopamine transport. Amphetamine
binds to the orthosteric binding site of DAT and NET, thus acting as a competitive inhibitor by
preventing dopamine and norepinephrine from being transported [31]. Cocaine is a
nontransported psychostimulant and stabilizes DAT, NET, and SERT in an outward-open confor-
mation by binding to the orthosteric site [42], an example of a classical competitive inhibitor that
also prevents uptake of physiological substrates. Ibogaine, however, is another nontransported
psychostimulant that was initially recognized as an inhibitor binding preferentially to an inward-450 Trends in Pharmacological Sciences, July 2020, Vol. 41, No. 7
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recent structure of SERT in complex with ibogaine, however, clearly shows an ibogaine molecule
bound to the orthosteric site [45]. Hence, it has now to be classified as an atypical, noncompet-
itive inhibitor [46]: it induces a conformational transition to the inward-facing state (by contrast to
cocaine [44] and other competitive inhibitors like paroxetine [26]). The orthosteric binding site is
thereby stabilized in an inward-facing conformation, which is not accessible from the extracellular
side, thus leading to this complex behavior of noncompetitive inhibition [45].
Hence, there is considerable heterogeneity among the ligands that bind to NTTs; the wide range
of these obviously orthogonally differing interaction patterns results in a rich pharmacology [46].
Moreover, given the pharmacological importance of this protein class, there is potential to de-
velop agents with a different pharmacological function, such as use-dependency (see
Glossary) or enhancement of transport activity: only allosterically bound compounds would be
able to provide such promising features.
The Principles of Allosteric Modulation
Allosteric modulation or allostery is a widespread phenomenon; one of the first reports was the
feedback regulation in deaminases [47,48]. In general, ligands bind to a protein within an inherent
binding site, the orthosteric site. However, proteins may also possess one or more alternative bind-
ing sites not targeted by the endogenous or common compounds. These are termed secondary or
allosteric sites [49,50]. Ligand binding to an allosteric site transmits an effect (positive or negative) to
other parts of the protein, thereby modulating function and/or activity of the orthosteric site, leading
to an ‘action-at-a-distance’ (Figure 2A). Accordingly, allosteric ligands likely change the conforma-
tion or the conformational dynamics of the protein and thereby modulate the access or binding of
ligands to the orthosteric site. However, other activity-modulating possibilities have also been pro-
posed, such as that allosteric binding leads to a change in the energetic barrier (represented by
ΔG), thus affecting the kinetics of biological processes [51] (Figure 2B). In some instances, allostery
cannot be easily explained, as seen with the example of the complex behavior of ibogaine (earlier).
Box 2 provides a brief overview of allostery models proposed in the field. In transport proteins, the
situation is more complex as ligands not only bind to proteins, but they may be translocated to the
intracellular side by inducing the transporter transition from an outward-facing to an inward-facing
conformation. Thus, allosteric ligands may increase the intrinsic transport rate, induce or inhibit re-
verse transport operation, termed efflux, or simply bind to block or slow down protein function.
The use of allosteric modulators rather than orthosteric ligands offers several pharmacological
and therapeutic advantages:
(i) Ligands for the orthosteric site are often analogs of the endogenous ligand and accordingly
cause potential side effects by also affecting other proteins targeted by the same endoge-
nous ligand. Allosteric binding sites do not possess the same structural conservation and
could have higher specificity with fewer side effects.
(ii) Allosteric modulators do not have to be activators per se, but could change the activity of
the protein’s intrinsic function in specific conditions (e.g., in the presence of the endogenous
ligand).
(iii) They can also possess use-dependency, being more active modulators when the proteins
have increased activity [52].
Approaching the Energetic Dimension of Allostery
Several approaches have been developed to investigate the allosteric nature of ligands. Simple
analytical approaches such as the Hill-Langmuir equation can be used to obtain an indicationTrends in Pharmacological Sciences, July 2020, Vol. 41, No. 7 451
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Figure 2. Allosteric Modulators and the ‘Action-at-a-Distance’. Structural and energetic view. (A) Comparison
between the effect mediated by a ligand (blue) interacting with the orthosteric site (yellow, left) and the ‘action-at-a-
distance’ mediated by a ligand (cyan, right) interacting with an allosteric site (light cyan, right). The ‘action-at-a-distance’
can be seen from a structural or a nonstructural point of view. From a structural point of view, the binding of the ligand
determines a cascade of conformational changes that can be sensed by the different domains and transmitted to the
orthosteric site (unbroken arrows). From a nonstructural point of view instead, allostery may determine its effect by an
infinite number of microstates that include changes in entropy and enthalpy, represented by changes in the Gibbs free
energy (ΔG). (B) In order to elicit an effect, the enzymatic reaction has to overcome its own energetic barrier (ΔG, grey).
Allosteric ligands increase or decrease the ΔG of the reaction according to their activity as negative- or positive allosteric
modulators (NAM, red or PAM, blue) respectively.
Trends in Pharmacological Sciencesof allostery [53]. Different methods are described in Box 1. Observations based on thesemethods
have led to the development of general models for describing the binding of ligands to proteins
and allostery.
The first model proposed for allostery was the ‘conformational selection model’. This model
assumes that the high affinity relaxed (R) state and the low affinity tensed (T) state of a pro-
tein, pre-exist in equilibrium for a protein homo-oligomer with tightly coupled protomers [54].
Although other models have been developed, the conformational selection model is the one
that obtained the largest support and was subsequently expanded (Box 2). The develop-
ment of new computational approaches opened the way to a more in-depth study of alloste-
ric connectivity or pathways from an energetic point of view: if a state within one domain
undergoes conformational changes, the interaction energy can either decrease or increase452 Trends in Pharmacological Sciences, July 2020, Vol. 41, No. 7
Box 2. Overview of Different Allostery Models
At the start of the 20th century, changes in pH or in the concentration of CO2 were found to modulate oxygen binding to
hemoglobin [120]. Later, work on the feedback mechanism of L-threonine deaminase revealed the existence of a different
and nonoverlapping binding site acting ‘at-a-distance’ on the central binding site [47]. Subsequently, the process was
termed ‘allosteric’ binding [48]. These observations initiated the conceptualization of the conformation-selection model,
also known as the ‘Monod-Wyman-Changeux’ (MWC) model, which assumes that ligands prefer one of the two states
that the protein adopts at equilibrium. These two states are commonly termed the ‘relaxed’ (R) and ‘tensed’ (T) state. Upon
ligand-binding, one conformation is selected. As the transitions between the R and T state are cooperative and include all
protomers, ligand binding transduces a signal to all protomers through few discrete conformations [54]. As an alternative
to the MWC-model, Koshland, Nemethy, and Filmer proposed the ‘induced-fit’model (or KNFmodel). This model predicts
a structural change only in response to binding of one or more ligands, which is symmetrically communicated to all
protomers [121]. Both the conformational-selection and the induced-fit models rely on a series of discrete conformational
rearrangements, without considering changes in the energy landscape involved in allosteric modulation. As such, they
were limited in explaining a number of effects. (i) Allosteric effects can occur without obvious structural changes
[122,123]. (ii) Mutations of surface exposed residues can modulate the function of the active site, while not showing stable
interactions with other residues [124,125]. (iii) Allosteric signal transmission between the allosteric and the orthosteric site
can also occur in the absence of an obvious connection between the two sites [126,127]. (iv) Binding of ligands to the
orthosteric or allosteric site may not be correlated with protein stability changes [128,129]. (v) Negative cooperativity
may not be described by the induced-fit or conformational-selection model [128].
To overcome the limitation of excluding energetic considerations, the ‘ensemble allostery model’ and the ‘allosteric Ising
model’ (AIM) have been proposed [55,130]. AIM, in particular, bridges thermodynamic and structural aspects using a sta-
tistical ensemble approach.
Trends in Pharmacological Sciencesand therefore stabilize or destabilize a conformation in a second domain [55]. The differences
in energy between states can be mathematically described to understand the free energy
contribution for the transition between different possible states. Accordingly, the change in
interaction energy allows individual domains to sense each other [55]: when a ligand binds
to the high affinity state, the free energy of ligand binding stabilizes this state and leads to
a redistribution of forces and conformations within the protein ensemble. Binding of an
effector molecule stabilizes the effector binding domain, which can in turn stabilize (positive
coupling) or destabilize (negative coupling) the high affinity state in the second domain [55].
Entropy and changes in entropy should therefore also be included, as allostery can originate
from changes in protein dynamics or conformational distribution upon ligand binding, without
large changes in enthalpy [56].
The field of G protein-coupled receptors (GPCRs) has been at the forefront in development
and discussion of theoretical aspects of allostery in membrane proteins [50,57–59]. It has
not received much attention in the case of NTTs. However, many of the basic allosteric
principles in GPCRs do not apply to transport proteins, hence some new concepts have to
be introduced.
Allosteric Modulators of NTTs: Making Sense of the Current Knowledge
Recent studies on the pharmacology of NTTs have established the heterogeneity among com-
pounds as described earlier, which initially called to mind the GPCR pharmacology complexity
[11,46,60]. In the case of NTTs, only a few crystal structures are available and only a small part
of them show compounds bound in allosteric sites [61,62]. In addition, only in a few cases has
the position of the compounds been confirmed by various complementary methods, such as
photoaffinity labeling, mutagenesis studies, or binding experiments using radiolabeled ligands. In-
deed, all these methods, including crystallization, need to be considered carefully and supported
by individual accessory methodologies. To date, there are only a few examples where information
on the exact binding locus in allosteric sites exists (see later). Therefore, this needs to be declared
as one of the most important outstanding questions.Trends in Pharmacological Sciences, July 2020, Vol. 41, No. 7 453
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Drugs acting at NTTsmay be divided into those binding to the orthosteric or S1-site, the vestibule
of the transporter, the S2-site, or to sites outside of the transport pathway (e.g., Zn2+-binding in
DAT and in EAATs) or to the oligomerization domain (e.g., UCPH-101 in EAATs). Ligands and
their respective binding site are shown in Figure 3 (Key Figure).
If, on the one hand, this structural classification helps to compare the pharmacology of different
NTTs, it does not provide any information from a functional point of view. In the case of
GPCRs, it has been established that compounds may either be classified as negative or positive
allosteric modulators (NAMs or PAMs) [50]. While this terminology may still be used in the case of
NTTs, the coexistence of separate functional processes (i.e., influx and efflux) implies that a com-
pound does not necessarily affect both processes in the same way. A compound working as a
NAM on uptake may have no effect, a similar effect, or an opposite effect when it comes to efflux.
Also, a compound that is a NAM on substrate transport may enhance the binding of an
orthosteric bound inhibitor and, therefore, act as a PAM in that respect (Box 3). For the sake of
simplicity, in the following we will only classify NAMs and PAMs of uptake; since there are only
a few modulators of efflux, they are briefly described in Box 3.
NAMs: Simply Inhibiting Uptake?
The existence of allosteric sites in SERT was postulated almost four decades ago [63,64], based
on the observation that the dissociation of a prebound radiolabeled tracer was inhibited. The rate
of ligand dissociation is a function of the intrinsic stability of the protein–ligand complex. If a sec-
ond ligand reduces the dissociation rate of the first ligand, then this is most likely caused by an
allosteric mechanism, in which the second ligand increases the energetic barrier of ligand disso-
ciation by a conformational change, by further stabilizing the bound state or just obstructing the
path of ligand dissociation. In SERT, a variety of ligands were described to inhibit the dissociation
of [3H]citalopram. The most potent one was the selective serotonin reuptake inhibitor citalopram,
but also the related compounds paroxetine and sertraline showed significant effects, while fluox-
etine, venlafaxine, and duloxetine had no effects [65,66]. Serotonin has also been shown to exert
an allosteric effect on the dissociation of [3H]imipramine, although with a very low potency [67].
Even though these early observations supported the existence of two binding sites in SERT, it
was not until three decades later that the sites were mapped: first, the orthosteric or S1-site in
the center of the protein [68] and subsequently, the allosteric or S2-site in the extracellular vesti-
bule, located in the entry path to the orthosteric binding site S1 [66] (Figure 3A). The allosteric ef-
fect was proposed to be due to steric hindrance of the exit pathway for the S1-bound radioligand.
The molecular models were substantiated by mutagenesis of residues in the S2-site, decreasing
allosteric binding. Indeed, SERT-G402H completely ablated allosteric binding of the tested li-
gands [66]. Atomic force microscopy (AFM; Box 1) experiments using S-citalopram as the
‘probe’ [69] and the crystal structure of human SERT [61] confirmed the presence of two
citalopram binding sites in SERT. However, by contrast to previous [3H]citalopram dissociation
experiments [65], no sertraline moieties have been found in the S2-site [70].
To date, all currently known selective serotonin reuptake inhibitors and tricyclic antidepressants
such as clomipramine bind to the S1-site with higher affinity than to the S2-site [64]. Themost po-
tent S2-bound ligand was S-citalopram, but its affinity is still about 5 μM, approximately 1000-fold
lower than its affinity for the S1-site (Kd ~5 nM). Recently, a ligand (Lu AF60097) was found that
had an S2-site affinity of ~30 nM and an S1-site affinity of around 300 nM [71] (Figure 3A). These
results show that it is possible to generate compounds with both high S2-site affinity and selec-
tivity relative to the S1-site, opening the possibility of approaching therapeutic effects by targeting
the S2-site. Moreover, the study shows that Lu AF60097 was able to potentiate the binding of454 Trends in Pharmacological Sciences, July 2020, Vol. 41, No. 7
Key Figure
Localization of Orthosteric and Allosteric Binding Sites in the Two Main
Classes of Neurotransmitter Transporters (NTTs)
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Figure 3. (A) Structure of solute carrier 6 (SLC6) transporter family, which includes the transporters for serotonin
norepinephrine, dopamine, and glycine; orthosteric and allosteric binding sites that have been described to date are
highlighted in different colors. Examples of compounds modulating such sites are also shown. Red: orthosteric binding
site, also referred to as S1-site, with two examples of compounds binding these [e.g., cocaine and D-amphetamine (D-
AMPH) in monoamine transporters (MAT)]. Cyan: S2-site in serotonin transporter (SERT) has been shown to be targeted
by S-citalopram and Lu AF60097. Black: additional binding site recently proposed in SERT with its allosteric modulato
ATM7. Orange: Zn2+ binding site. Green: allosteric binding site in GlyT2 amenable to targeting of specific acylamino acids
such as NAGly and ODLys. Purple: binding site described in the dopamine transporter (DAT) and modulated by KM822
In the middle are highlighted the compounds shown to act as allosteric modulators, but whose structural determinants are
still uncharacterized. The table at the bottom highlights which transporter is targeted by the respective inhibitor in the
tridimensional map of SLC6 transporters (color code matched). (B) Structure of solute carrier 1 (SLC1) transporter family
including various excitatory amino acid transporters (EAATs 1-5); orthosteric and allosteric binding sites that have been
described to date are highlighted in different colors. Blue: central binding site, targeted, for instance, by the nonselective
(Figure legend continued at the bottom of the next page.
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Box 3. Modulation of Efflux: Positive and Negative Modulatory Effects
The PAM ATM7 has been shown to increase MDMA-triggered, SERT-mediated [3H]5-HT release [102]. SoRI-9804 and
SoRI-20040, instead, can work as NAM of both uptake and efflux [73]. However, Parawixin1 and SRI-29574 allosterically
inhibit EAAT2- and DAT-uptake, respectively, without affecting efflux [60,96]. The complex interplay between uptake and
efflux has been observed also in the case of the SERT-selective, para-trifluoromethyl-methcathinone (p-CF3-MCAT). A
point mutation in the S2-site of SERT could modulate the p-CF3-MCAT-mediated partial release of [
3H]5-HT but not
the full release mediated by para-chloro-amphetamine, suggesting that the S2-site of SERT may work as a regulatory
site for substrate efflux [29].
In addition, the endogenous trace element Zn2+ has been shown to enhance DAT-mediated, amphetamine-induced re-
lease [104,113]. It has been suggested that Zn2+ may work as an endogenous modulator of dopamine neurons with re-
spect to their firing frequency by enhancing DAT-mediated release of dopamine [114].
Drug-induced efflux has been studied mainly at monoamine transporters, as discussed above. In the case of a large pro-
portion of allosteric NTTmodulators, the effect on efflux was not determined. Thismay have to dowith: (i) the fact that efflux
is still an understudied phenomenon for some NTTs and/or ligands; and (ii) ‘amphetamine-type’ releasers are not available
for a large number of transporters. In the case of EAAT1, reverse transport has mainly been described under pathophys-
iological conditions [38,116] and therefore the development of compounds leading to an increase in extracellular gluta-
mate seemed pointless, if not disadvantageous, with respect to excitotoxicity. Consequently, for several, if not most,
compounds, only the uptake has been characterized (see main text for discussion).
Trends in Pharmacological Sciencesimipramine to SERT, opening the possibility of decreasing its dosage and thus alleviating some of
the detrimental side effects of imipramine treatment [71].
A similar site has also been hypothesized for DAT and NET. However, none of the tested com-
pounds could slow down the dissociation of the prebound GBR12935, which binds to the
orthosteric site in DAT, and only sertraline could slow down the dissociation of [3H]nisoxetine
in NET [72]. Recently, it was reported that two quinolone analogs, SoRI-9804 and SoRI-
20040, are able to inhibit both uptake and efflux of [3H]-dopamine, but only with partial efficacy
(40–60%). The partial efficacy is present even at saturating concentrations, suggesting that its
binding must halt the catalytic efficiency [i.e., maximal transport velocity (Vmax)], without being a
competitive inhibitor [73]. Similar to allosteric activity of S-citalopram in SERT, SoRI-9804 and
SoRI-20040 reduced the dissociation of a radioligand prebound in the orthosteric site of DAT
[74]. By contrast, SoRI-20041 partially inhibits dopamine uptake without affecting DAT-
mediated release [73]. Subsequently, the SoRI-20041 structure was optimized in order to in-
crease the affinity for DAT. This resulted in SRI-29574, a high-affinity DAT inhibitor, showing
similar pharmacological features to its parent compound [60]. The binding site of these com-
pounds is still unknown, but regardless of their potential clinical application, their unconven-
tional transporter pharmacology may allow better elucidation of the complex transport
mechanism of NTTs.
By using an in silico-based approach, the ligand KM822 was recently identified as an allosteric
inhibitor of DAT (Figure 3A) [75]. KM822 shows a fairly good selectivity towards DAT and stabilizes
it in the outward-open conformation. Saturation of [3H]-dopamine uptake experiments show a
mixed profile as voltammetry experiments performed in acute striatal slices demonstrate that
KM822 reduces cocaine inhibition of dopamine uptake without affecting dopamine release.and competitive inhibitor of the EAATs, DL-threo-β-benzyloxyaspartic acid (TBOA). Red: trimerization domain (TMD) shown to
bind UCPH-101 in EAAT1 and suggested as binding site for PbTx1.2.3 and GT949 in EAAT2. Orange: Zn2+ binding site
proposed for EAAT1, EAAT2, and EAAT4. The table at the bottom highlights which transporter is targeted by the
respective inhibitor in the tridimensional map of SLC1 transporters (color code matched).
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Trends in Pharmacological SciencesMoreover, KM822 reduces the psychostimulant-mediated increase in locomotion, suggesting it
as a possible candidate to treat addiction [75].
By contrast, the GlyT inhibitor bitopertin is promising from a clinical point of view [76]. GlyT1 reg-
ulates glycine dynamics at both inhibitory and excitatory synapses. Indeed, glycine acts on excit-
atory synapses as a coagonist with glutamate at N-methyl-d-aspartic acid (NMDA) receptors and
on inhibitory synapses, activating the inhibitory glycine receptors [77]. Bitopertin shows selectivity
towards GlyT1 over GlyT2 and reduces Vmax of [
3H]glycine uptake without changing its Km, an in-
dication of allosteric inhibition [78,79]. Bitopertin normalized amphetamine-induced
hyperlocomotion and phencyclidine-induced amphetamine-sensitization, indicating its ability to
modulate a state of dopaminergic dysregulation [79]. This effect has been linked to the ability of
glycine to potentiate NMDA-stimulated GABA release in the corpus striatum, which in turn
would inhibit dopamine release [80]. However, despite these promising early results, bitopertin
did not pass Phase III clinical trials for the treatment of negative symptoms of schizophrenia
[81,82]. Nevertheless, the outstanding preclinical and early clinical data of bitopertin led to its in-
vestigation in combination with other drugsi and for the treatment of other conditionsii.
Furthermore, promising results for the treatment of chronic pain [83] have been obtained by non-
competitive inhibition of GlyT2 by N-arachidonyl-glycine (NAGly) at low μM affinity [84]. More re-
cently, analogs of NAGly with nanomolar affinity have been developed [85]. Based on
computational and mutational studies, the binding site for the GlyT2 ligand oleoyl-D-lysine
(ODLys) has been suggested to be located in a crevice between the extracellular loop 4 and
trimerization domain 5 (Figure 3A) [86]. This site differs from the S1- and S2-site identified in
other NTTs and suggests that NTTs can be pharmacologically modulated through a variety of dif-
ferent binding sites (Figure 3). ODLys has a fast brain penetration and showed activity in a rat
model of neuropathic pain [87]. Importantly, ODLys displayed a unique, fast reversibility when
compared with other GlyT2 inhibitors [87]. Some of these lipids described can act as partial, non-
competitive inhibitors, reaching maximal levels of inhibition that range from 50 to 90%. It should
be emphasized that partial inhibition is an underexplored concept that may provide better thera-
peutic outcomes, as partial inhibitors would slow clearance but not stop reuptake completely
[87,88].
In the case of the EAATs, the EAAT-1 selective inhibitor UCPH-101 reduces the catalytic activity
of glutamate by EAAT-1 without affecting its Km. Therefore, the pharmacology of UCPH-101 is
allosteric in nature, by contrast to the nonselective and competitive inhibitory profile of DL-threo-
β-benzyloxyaspartic acid (TBOA) [62]. EAATs are trimeric structures [89], each with a transport
domain functioning independently of the other (Figure 3B). Mutagenesis studies have located
their allosteric binding site at the rim of the trimerization domain and therefore far from the
orthosteric binding site [90], suggesting that the monomers might not function as completely in-
dependent entities. The observations are supported by an outward-facing EAAT-1 crystal struc-
ture in complex with UCPH-101 [62]. Despite a hypothetical benefit of UCPH-101, for instance,
by blockage of exaggerated EAAT-1 mediated glutamate efflux to alleviate negative effects of an-
oxia or ischemia [38], its use is confined to in vitro research because of its poor blood–brain barrier
permeability [91].
PAMs: Boosting Transporter Activity
The development of PAMs for transporters may spark great interest, specifically when it comes to
transporters involved in the buffering of excitatory neurotransmitters such as glutamate or aspar-
tate. PAMs may thus reduce excitotoxic neuronal damage [92]. They can influence membrane
potential either via electrogenic transport, or through generation of an uncoupled conductanceTrends in Pharmacological Sciences, July 2020, Vol. 41, No. 7 457
Trends in Pharmacological Sciences[93,94]. An example of an NTT potentiator is the venom extract of the spider Parawixia bistriata,
known as Parawixin1 or PbTx1.2.3. Parawixin1 is an EAAT-2 selective potentiator. It enhances
glutamate uptake in cortical synaptosomal preparations, therefore promising to protect against
neuronal death in a rodent model of induced ischemia [95]. Further studies have proposed that
Parawixin1 acts by accelerating a potassium-dependent return step of the transporter [96]. The
Parawixin1 binding site has been localized to the EAAT2 trimerization domain [97], which has
also been involved in the binding of UCPH-101, a recently developed NAM of EAAT1
(Figure 3B). This suggests that this part of the EAAT proteins could bear an allosteric site that
could be targeted for the development of novel EAAT allosteric modulators [98]. Unfortunately,
the exact components of the Parawixin1 extract are still unknown, but by making use of the ex-
tensive mutagenesis study carried out for Parawixin1, it was possible to tailor a series of com-
pounds interacting with the EAAT2 trimerization domain [97]. One of these compounds, GT949
(Figure 3B), showed results comparable with Parawixin1 in increasing EAAT2 uptake [99].
In SERT, mutagenesis studies in extracellular loops 1 and 3 established residues that control
transporter function [100,101]. By a virtual screen of several SERT-inhibitors, the ligand
ATM7 was identified; this is able to reduce both Bmax and KD of [
3H]paroxetine binding, consis-
tent with an allosteric mechanism of action or an atypical inhibitor mode of action, binding to the
orthosteric binding site in an inward-facing SERT. Moreover, cysteine accessibility analysis re-
vealed that ATM7 stabilizes the outward-open conformation of SERT [102]. Finally, ATM7 in-
creased 5-HT-transport and potentiates MDMA (ecstasy)-triggered reverse transport by
SERT [102], thus indicating that ATM7 changes energy barriers along the path of the transport
cycle.
Mixed NAM–PAM Behavior: The Complex Case of Zinc
Zinc (Zn2+) is present in many parts of the brain and modulates a number of receptors and
transporters and is thus involved in regulating neurotransmission [103]. Among the group of
NTTs, it has been shown that Zn2+ modulates the reuptake and release process of DAT, but
not SERT or NET [104,105], and it also modulates glutamate and glycine transporters
[106–109].
In DAT, but not SERT or NET, four residues at the extracellular side (Glu206, His193, His 375, and
Asp 296) coordinate a binding site for Zn2+ [110–112]. The Zn2+ binding site is completely segre-
gated from the substrate binding site and from the S2-site in the extracellular vestibule of NTTs
(Figure 3A). Binding of Zn2+ to DAT elicits multiple functions: it stabilizes the DAT outward-open
conformation and thereby promotes the binding of cocaine, which likely stabilizes the same con-
formation [42,112]. In addition, the redistribution of the conformational ensemble towards an
outward-open state by Zn2+ binding has pronounced effects on dopamine transport [104,110],
eliciting a biphasic effect with transport stimulatory properties at low concentrations and inhibitory
properties at higher concentrations [19]. However, even though Zn2+ inhibits dopamine transport
in the higher concentrations, it is inhibited to about 50–75%of the initial transport velocity [30,113]
at low concentrations. Only millimolar Zn2+ concentrations will completely inhibit dopamine trans-
port, probably by an indirect toxic effect. The potentiation of transport velocity by Zn2+ [30,113]
opens up the possibility that compounds could increase dopamine clearance, and also, for ex-
ample, rescue loss-of-function DAT mutants or alleviate symptoms in diseases caused by in-
creased dopamine signaling [39]. Importantly, Zn2+ has been found to also bind allosterically to
GlyT1, EAAT1, and EAAT4. However, in all these cases, Zn2+ acts as a NAM and its binding is
coordinated by pairs of histidine residues located far from the orthosteric site [107–109]. Zn2+
could be viewed as an endogenous allosteric modulator of NTTs, as has been suggested earlier
[114]. A detailed understanding of this complex mechanism of action of this important trace458 Trends in Pharmacological Sciences, July 2020, Vol. 41, No. 7
Outstanding Questions
Does the allosteric modulation of NTTs
have a physiological role?
How can we ascertain allosteric
binding sites in NTTs and pinpoint the
exact interaction partners?
Is it possible to implement the transport
cycle into the drug-development
process?
Is it possible to develop compounds
that specifically stabilize specific
conformations of the transporter? And
how are the different conformations of
NTTs transducing the signal into the
cell?
Is it possible to allosterically modulate
transporter-mediated efflux? How
could this be used pharmacologically/
clinically?
Trends in Pharmacological Scienceselement may form the basis for the development of small molecules able to act as NTT
potentiators.
Concluding Remarks and Future Perspectives
Allosteric sites have been largely exploited in pharmacology and especially in the field of
GPCRs and ion channels [50,115]. Targeting of such so-called ‘secondary sites’ allows tai-
loring of drugs around less conserved protein regions, which can potentially avoid off-target
effects [50]. The rather high degree of conservation of the orthosteric binding sites in NTTs
challenges exclusive targeting of specific transporter subtypes. Even if the selective seroto-
nin reuptake inhibitors were not developed as allosteric modulators, some of them have
shown moderate affinity for the S2-site. The S1- and S2-sites have been shown to be allo-
sterically coupled, at least in SERT [71]. However, whether there is a physiological role for
the S2-site remains unresolved and future work will be required (see Outstanding
Questions). In this sense, the recent discovery of Lu AF60097 [71] will help to elucidate
the role of the S2-site in SERT and its therapeutic potential. Moreover, the exact positioning
of allosterically active compounds within a given NTT is still elusive, to a large extent, and
needs to be assessed by a variety of different methodologies in parallel (see Outstanding
Questions).
In addition, the coupling between transporter-mediated substrate uptake and efflux has still to
be clarified: the fact that an abnormal basal efflux is seen in pathophysiological conditions,
that different compounds can selectively target uptake, efflux or both, suggests a complex in-
terplay between uptake and efflux that may be amenable to the development of innovative
therapeutics (see Outstanding Questions). The existence of transporter inhibitors that selec-
tively modulate only one of the two components [73] emphasizes the need to explore the sub-
strate transport cycle in further detail [14]. In addition, abnormal efflux of neurotransmitters
has been found after ischemic events [38,116], or with point mutations of NTTs associated
with neuropsychiatric disorders [40,41]. Unfortunately, while the transport cycle is receiving
ample attention in the case of monoamine transporters, it has not been thoroughly explored
in the case of other NTTs. For instance, it is still not known which part of the transport cycle
is stabilized by the EAAT-1 inhibitor UCPH-101 and which by the GlyT1 inhibitor bitopertin.
Nevertheless, addressing the possibility of specifically ‘locking’ the transporter in one or
more steps of its conformational cycle would be very relevant; there are several different ex-
amples where distinct conformational steps exist which could be targeted [16,18,19] (see
Outstanding Questions).
To date, the only clinically approved NTT inhibitors with allosteric properties belong to the family
of antidepressants (Table 1) and the clinical relevance of their allosteric modulatory effect is still
not fully understood. Indeed, compared with GPCRs and ion channels, allosteric modulation of
NTTs has received too little attention in past years [117], emphasizing the need to understand
the function of their regulatory site(s). Moreover, many secondary sites exist in different NTTs,
which may exert modulatory functions and may be targeted by exogenous or endogenous
modulators: the Zn2+ binding site discovered in DAT, EAAT1, EAAT4, and GlyT1 serves as
an example of the latter. The implementation of alternative tools for understanding how
drugs can affect the transport cycle, in combination with classical pharmacological assays,
may help in dissecting specific compound-related features and develop new therapeutic strat-
egies towards allosteric modulation in a rational manner (see Outstanding Questions). Above
all, an enhanced knowledge of allosteric modulation of NTTs may guide drug development pro-
cesses and lead to novel therapeutic strategies, most warranted in the area of neurological and
neuropsychiatric disorders [118].Trends in Pharmacological Sciences, July 2020, Vol. 41, No. 7 459
Table 1. List of the Currently Available Allosteric Modulators of NTTs with Their Alternative Names, Promising Preclinical Features, and Examples of
Clinical Testinga
Structure Compound Target Uptake Efflux Activity Stage Refs
O
N
N
F S- Citalopram or escitalopram SERT ↓ ↓ NAM Approved [64,66,119]
N
H N+
O O
NH2
O
F
Lu AF60097 SERT ↓ n.d. NAM Preclinical [71]
NH
N
N
N N
SRI-29574 DAT (also NET/SERT) ↓ – NAM Preclinical [60]
NH O
S
O
O NH
S
N
H
N
N
H N
H
KM822 DAT ↓ n.d. NAM Preclinical [75]
F
F F
O S
O
O
O
NN
NF
F
F
F
Bitopertin or RG1678; RO4917838 GlyT1 ↓ n.d. NAM Phase III [76,79,82]
N-arachidonyl
NH
O
OH
N-arachidonyl-glycine (NAGly) GlyT2 ↓ n.d. NAM Preclinical [86,87]
N-oleoyl
NH
O OH
NH2
N-oleoyl-D-lysine (ODLys) GlyT2 ↓ n.d. NAM Preclinical [86,87]
O
O
O
NH2
N
UCPH-101 EAAT1 ↓ n.d. NAM Preclinical [62,90]
n.d. Parawixin1 (PbTx1.2.3) EAAT2 ↑ – PAM Preclinical [96]
N+
N+
N
NN
N
N
H
O
H
H
O
GT949 EAAT2 ↑ n.d. PAM Preclinical [99]
N
N
N
O
NH
O
N S
NH2
O
NH2
ATM7 SERT ↑ ↑ PAM Preclinical [102]
aAbbreviations: DAT, dopamine transporter; EAAT, excitatory amino acid transporter; GlyT, glycine transporter; NAM, negative allosteric modulator; n.d., not determined;
NET, norepinephrine transporter; PAM, positive allosteric modulator; SERT, serotonin transporter, ↓, reduced; ↑, increased; –, no change.
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